Literature DB >> 7144619

[Active and passive immunization against hepatitis B virus infection].

H Colak.   

Abstract

Immune serum globulin and hepatitis B immunoglobulin are used for prevention and prophylaxis in hepatitis B virus infection. These are effective against pre- and postexposure cases. Hepatitis B immunoglobulin is more effective than immune serum globulin. Hepatitis B virus vaccines are prepared from HBsAg and its polypeptides. The vaccines prevent from hepatitis B infection in a high percentage. Antibody response for HBsAg vaccines are about 95 percent. Hemodialysis units personnel and patients, surgeons, dentists, male homosexuals and infants in endemic areas must be vaccinated with HBsAg vaccines.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7144619

Source DB:  PubMed          Journal:  Mikrobiyol Bul        ISSN: 0374-9096            Impact factor:   0.622


  7 in total

1.  ACE2 receptor usage reveals variation in susceptibility to SARS-CoV and SARS-CoV-2 infection among bat species.

Authors:  Huan Yan; Hengwu Jiao; Qianyun Liu; Zhen Zhang; Qing Xiong; Bing-Jun Wang; Xin Wang; Ming Guo; Lin-Fa Wang; Ke Lan; Yu Chen; Huabin Zhao
Journal:  Nat Ecol Evol       Date:  2021-03-01       Impact factor: 15.460

Review 2.  Heteromeric Solute Carriers: Function, Structure, Pathology and Pharmacology.

Authors:  Stephen J Fairweather; Nishank Shah; Stefan Brӧer
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Extrapulmonary manifestations of COVID-19.

Authors:  Aakriti Gupta; Mahesh V Madhavan; Kartik Sehgal; Nandini Nair; Shiwani Mahajan; Tejasav S Sehrawat; Behnood Bikdeli; Neha Ahluwalia; John C Ausiello; Elaine Y Wan; Daniel E Freedberg; Ajay J Kirtane; Sahil A Parikh; Mathew S Maurer; Anna S Nordvig; Domenico Accili; Joan M Bathon; Sumit Mohan; Kenneth A Bauer; Martin B Leon; Harlan M Krumholz; Nir Uriel; Mandeep R Mehra; Mitchell S V Elkind; Gregg W Stone; Allan Schwartz; David D Ho; John P Bilezikian; Donald W Landry
Journal:  Nat Med       Date:  2020-07-10       Impact factor: 53.440

Review 4.  COVID-19 Infection and Circulating Microparticles-Reviewing Evidence as Microthrombogenic Risk Factor for Cerebral Small Vessel Disease.

Authors:  Che Mohd Nasril Che Mohd Nassir; Sabarisah Hashim; Kah Keng Wong; Sanihah Abdul Halim; Nur Suhaila Idris; Nanthini Jayabalan; Dazhi Guo; Muzaimi Mustapha
Journal:  Mol Neurobiol       Date:  2021-06-26       Impact factor: 5.590

5.  Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections.

Authors:  Chao Zhang; Yifan Wang; Yuanfei Zhu; Caixuan Liu; Chenjian Gu; Shiqi Xu; Yalei Wang; Yu Zhou; Yanxing Wang; Wenyu Han; Xiaoyu Hong; Yong Yang; Xueyang Zhang; Tingfeng Wang; Cong Xu; Qin Hong; Shutian Wang; Qiaoyu Zhao; Weihua Qiao; Jinkai Zang; Liangliang Kong; Fangfang Wang; Haikun Wang; Di Qu; Dimitri Lavillette; Hong Tang; Qiang Deng; Youhua Xie; Yao Cong; Zhong Huang
Journal:  Nat Commun       Date:  2021-01-11       Impact factor: 14.919

6.  A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein.

Authors:  Cheolmin Kim; Dong-Kyun Ryu; Jihun Lee; Young-Il Kim; Ji-Min Seo; Yeon-Gil Kim; Jae-Hee Jeong; Minsoo Kim; Jong-In Kim; Pankyeom Kim; Jin Soo Bae; Eun Yeong Shim; Min Seob Lee; Man Su Kim; Hanmi Noh; Geun-Soo Park; Jae Sang Park; Dain Son; Yongjin An; Jeong No Lee; Ki-Sung Kwon; Joo-Yeon Lee; Hansaem Lee; Jeong-Sun Yang; Kyung-Chang Kim; Sung Soon Kim; Hye-Min Woo; Jun-Won Kim; Man-Seong Park; Kwang-Min Yu; Se-Mi Kim; Eun-Ha Kim; Su-Jin Park; Seong Tae Jeong; Chi Ho Yu; Youngjo Song; Se Hun Gu; Hanseul Oh; Bon-Sang Koo; Jung Joo Hong; Choong-Min Ryu; Wan Beom Park; Myoung-Don Oh; Young Ki Choi; Soo-Young Lee
Journal:  Nat Commun       Date:  2021-01-12       Impact factor: 14.919

7.  Bat and pangolin coronavirus spike glycoprotein structures provide insights into SARS-CoV-2 evolution.

Authors:  Shuyuan Zhang; Shuyuan Qiao; Jinfang Yu; Jianwei Zeng; Sisi Shan; Long Tian; Jun Lan; Linqi Zhang; Xinquan Wang
Journal:  Nat Commun       Date:  2021-03-11       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.